September 11th Webinar: Qualified Person for Pharmacovigilance (QPPV): Roles and Responsibilities - See Webinar section for further details

Welcome to ICON

ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies

In a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis.

We have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution.

These services are delivered by the following ICON Divisions.

ICON Central Laboratories - Global central laboratory services dedicated exclusively to clinical trials




ICON Clinical Research - Planning , management, execution and analysis of Phase IIb – IV clinical trials



ICON Contracting Solutions - Contract and permanent staffing solutions for pharmaceutical and biotech companies



ICON Development Solutions - Product development planning , early phase clinical development, and expertise in regulatory affairs, pk/ biopharmaceutics and bioanalytics



ICON Medical Imaging - Medical imaging based development solutions, including independent imaging review and database delivery to regulatory authorities





To view our 2007 Annual Report please click on an option below:


20F - 2007



IFRS Accounts - 2007





Letter to stockholders






Notice of AGM and Proxy Materials
&nbsp

Additional Proxy Materials




Second quarter 2008 results
by clicking on the button below:( Call on July 22nd , 2008 14:00GMT)


To listen to this call please click here.
>




ICON announces completion of “Stock Split”
ICON Medical Imaging Launches New Service to Boost..
AGM of ICON plc Approves “Stock Split”
ICON announces ADS Payment Date and NASDAQ Ex-Date..
ICON Enhances Its ICOPhone Technology Platform
ICON reports 49% increase in revenue and 52% incre..
ICON Medical Imaging Strengthens Cardiovascular Ex..
Proposed Bonus Share Issue to double number of sha..
ICON Partners with PHT for Handheld Electronic Pat..
 
the current time is :
 

ICON Japan
Japanese Version

 
  Disclaimer | Privacy Policy
North America South America Africa Europe Asia Australia